Information Provided By:
Fly News Breaks for December 6, 2019
SNY
Dec 6, 2019 | 06:26 EDT
Barclays analyst Emmanuel Papadakis downgraded Sanofi to Underweight from Equal Weight with a EUR 75 price target. The analyst continues to see "multiple challenges" for the company's Pharma business across several major franchises, and "limited scope" for upside from present share levels even on a sum-of-the-parts basis. Sanofi's "pipeline deficiency" has no easy or cheap fix, Papadakis tells investors in a research note.
News For SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.